Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Global Investment Group Seeks Opportunities in Early-Stage, Software-Based Digital Health Technologies

19 Nov

A global investment group invests through multiple vehicles and has over $1B targeted on healthcare and life science under management. The firm recently launched a new vehicle to invest in digital health technologies. The group will invest $0.5-1M, mainly in seed-series A companies developing software-based digital technologies.

The firm is interested in software-based digital health companies. The group will not invest in wearables or smart devices. The firm invests primarily in B2B or B2B2C companies, and looks for technologies that have clear cost saving or revenue generating aspect for clients. While the firm will invest globally, they are looking for companies targeting the US market.

The firm is a very active investor, leveraging their network and broad-cross sector activity to help their portfolio companies. The group is looking for companies that, at minimum, have a viable understanding of the US healthcare market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Venture Capital Firm Invests Up to $25M in Therapeutics, With Strong Interests in Platform Technologies Based in North America

19 Nov

A firm with offices in the USA invests in seed and Series A rounds, and has a strong preference for being the first institutional investor in a company. The firm typically reserves a total of $25 million to invest over the life of a portfolio company. The firm invests in the USA and Canada, and typically makes about 5 allocations per year.

The firm is primarily focused on therapeutics, and generally will no longer invest in technologies with a medical device regulatory pathway. The firm prefers to invest in platform technologies that have attained significant preclinical proof of concept data, preferably with published data and evidence that shows reproduction of theory. The firm prefers that platform technologies have potential to bring therapeutics to market in the short-term. The firm will consider therapeutic opportunities in any indication space and is agnostic to modality (i.e. small molecule, large molecule, cell/gene therapy). Additionally, the firm invests in biotech research tools, such as sequencing technologies and discovery platforms.

The firm prefers to work with strong scientific teams. The firm invests only in the USA and Canada, and does not consider international opportunities unless the company has a significant US presence. The firm generally does not invest in companies that have previously received investments from an institutional investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Chinese Multi-Billion Dollar Fund Can Invest Up to $50M In All Life Science & Healthcare Opportunities with China Market Potential

19 Nov

A venture firm based in China has a multi-billion dollar fund and is interested in companies raising seed/angel to Series A rounds and provides investments that can range up to $50M depending on the opportunity. Series B round will also be considered occasionally in terms of the potentiality. The firm seeks opportunities globally, though it has a preference for companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Seed Fund Focuses on Applied AI Technologies Within Digital Health, Diagnostics, and R&D Services

19 Nov

A seed fund based in the USA focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based VC Firm Invests Up to €20M in Innovative Therapeutics Addressing Unmet Need, Open to Various Modalities

12 Nov

A leading European independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. The firm has raised three funds to date. The investments typically range from €5 million to €20 million, including additional capital for follow-on investments.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Life Science Investment Arm of Global PE Firm Invests Up to $20M in Clinical Stage Therapeutics, Medical Devices, Diagnostics

12 Nov

A life science investment arm of a global private equity has offices across the USA. The fund may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide.

The firm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the firm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the firm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The firm will consider investments in any indication or technology area.

The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, the firm is open to working to fill or change the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Venture Capital Firm Invests in Medical Devices & Diagnostics Companies in Oncology, Cardiovascular Disease, and More

12 Nov

A venture capital firm based in the USA is specializing in early stage opportunities in med-tech, diagnostics, and instruments. Currently, the firm has a total AUM of $125 million. Typically, the firm initially invests in a start-up at the early stage, but reserves capital for participation later on. The firm typically makes a first investment in the range of $1-3 million, but is open to making larger or smaller allocations as opportunities arise. The firm expects to invest a total in the range of $7-12 million in a given portfolio company as it makes progress toward a successful exit. The firm prefers to act as a lead investor for early stage deals.

The firm is most interested in companies developing medical devices, diagnostics tools and instrumentation. The firm is looking for companies targeting global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. The firm is willing to invest in companies that are pre-prototype as well as those that have a working prototype of their product.

The firm looks to act as a long term strategic partner with its portfolio companies. The firm looks for experienced management teams and generally looks to take a board seat into companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: